Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 05 Oct, 21:10 UTC

Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi’s second big rare disease move this year, following the acquisition of global rights to an…

businessscience

Sources

• T2Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio AcquisitionFierce Biotech / Fierce Healthcare / MedCity / GEN05 Oct, 21:10